Janus Henderson Group PLC Increases Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Janus Henderson Group PLC raised its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 259.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 849,410 shares of the company's stock after acquiring an additional 613,294 shares during the quarter. Janus Henderson Group PLC owned approximately 2.43% of Oruka Therapeutics worth $16,415,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Oruka Therapeutics by 17.7% during the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after purchasing an additional 830,000 shares during the last quarter. Fairmount Funds Management LLC increased its position in Oruka Therapeutics by 5.0% during the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after buying an additional 160,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after acquiring an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Oruka Therapeutics by 374.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after acquiring an additional 1,047,245 shares in the last quarter. Finally, Braidwell LP lifted its position in shares of Oruka Therapeutics by 122.5% in the fourth quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after acquiring an additional 631,950 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ORKA. Wedbush reissued an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday. HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wolfe Research began coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $39.86.

Oruka Therapeutics Stock Up 2.5%

Shares of ORKA stock traded up $0.25 on Monday, reaching $10.31. 160,168 shares of the stock were exchanged, compared to its average volume of 227,762. The stock has a market cap of $386.02 million, a P/E ratio of -1.65 and a beta of 0.25. The firm has a 50 day moving average of $9.86 and a two-hundred day moving average of $14.68. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.